ALFA Finder| Value | ₹9.11 Cr |
|---|
NSE filing, NSE: SAROJA. Summary written from the filing by ALFA Finder's alert engine.
Saroja Pharma Industries India Ltd: key numbers
- Share price
- ₹38.00
- Market cap
- ₹15.28 Cr
- Revenue (annual)
- ₹70.13 Cr
- Net profit (annual)
- ₹1.61 Cr
- P/E (TTM)
- 9.5×Sector 35.5×
- Promoter holding
- 73.02%
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Saroja Pharma Industries India Ltd
All →Saroja Pharma Industries India Management Change
Saroja Pharma's statutory auditor Pravin Chandak & Associates resigned effective October 26, 2026, citing pre-occupation. The company will appoint new auditors to fill the vacancy.
Saroja Pharma Industries India Management Change
Mr. Ravindra Shivaji Salaskar has resigned as Whole-time Director of Saroja Pharma Industries India Limited, effective October 5, 2026. He continues as the company's CFO.
Saroja Pharma Industries India Annual General Meeting
Saroja Pharma Industries India Limited held its 8th Annual General Meeting on September 30, 2026, through video conferencing to transact business.
Saroja Pharma Industries India Management Change
Saroja Pharma Industries India Limited appointed Mr. Ravindra Shivaji Salaskar as Chief Financial Officer. He currently serves as a Whole-time Director of the company.
Saroja Pharma Industries India Annual General Meeting
Saroja Pharma Industries India Limited has issued a notice for its 8th Annual General Meeting, scheduled to be held on September 30, 2026, through video conferencing.
Saroja Pharma Industries India Board Meeting Outcome
Saroja Pharma Industries approved its draft Board Report, Management Discussion and Analysis Report, and the notice for its 8th Annual General Meeting.
Other fund raise announcements
All →Om Metallogic Fund Raise
Om Metallogic Ltd intimated a board meeting on 14 November 2026 to approve rights issue issue price, entitlement ratio, record date and issue dates. The rights issue follows BSE in-principle approval.
Virinchi Fund Raise of ₹30 Cr
Virinchi's board approved a Rs 30 Crore preferential issue of 2 crore convertible warrants at Rs 15 each. Subject to EGM approval, allottees include promoter Viswanath Kompella.
- Value
- ₹30.00 Cr
- Execution
- Warrant tenure not exceeding 18 months from allotment
IIFL Finance Fund Raise of ₹6,414 Cr
IIFL Finance's board approved a preferential issue of convertible preference shares and warrants worth Rs.6,414.20 Crore. Shareholder approval is needed at a 4 December EGM.
- Value
- ₹6,414 Cr
Bajaj Finance Fund Raise of ₹5,800 Cr
Bajaj Finance's special committee approved issuing 5.74 crore warrants to promoter Bajaj Finserv at ₹1,010 each. The issue raises about ₹5,800 crore.
- Value
- ₹5,800 Cr
Cholamandalam Investment & Finance Company Fund Raise of ₹5,000 Cr
Cholamandalam Investment sent shareholders a postal ballot notice seeking approval for a Rs 5,000 crore QIP. E-voting runs November 10 to December 9, 2026.
- Value
- ₹5,000 Cr
- Execution
- Allotment to be completed within 365 days of shareholder approval
HB Leasing & Finance Co Fund Raise
HB Leasing's board discussed fund-raising options on November 9, 2026, including equity and preference shares. No quantum or pricing is decided; advisers will be consulted.